The group's principal activity is to develop products for targeted delivery of anti-cancer agents, including radiopharmaceuticals, to tumor sites. The group's product strtm (skeletal targeted radiotherapy) is developed to treat multiple myeloma, a cancer of the body's antibody-producing cells originating in the bone marrow. This reduces exposure of healthy tissues other than bone to the potentially toxic effects of the radiation. The group's str product consists of a bone-seeking molecule called dotmp, which deposits the radioactive substance, holmium-166, in the skeleton. The operations are carried on in the United States.
